https://stockhub.co/index.php?action=history&feed=atom&title=PharmaEssentia_Corporation 2026-05-26T11:11:13Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=PharmaEssentia_Corporation&diff=69449&oldid=prev 2022-09-23T19:33:06Z

<p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, chronic neutrophilic leukemia, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, chronic neutrophilic leukemia, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of liver cancer. The company also licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div>

95.149.241.133